Press

FSD Pharma Inc. Closes Non-Brokered Private Placement

Dec 6 • 7 min read

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (the “Company” or “FSD“), is pleased to announce that, further to its news release on November 27, 2023, it has closed a non-brokered private placement and issued 24 class A multiple voting shares (“Class A Shares“) of the Company at a price of $1.90 per Class A Share for gross proceeds…

Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment

Dec 5 • 3 min read

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced achievement of positive results in addiction treatment for its revolutionary treatment targeting cocaine addiction. This groundbreaking development is centered around the company’s innovative psychedelic…

Mental Health Psychedelic Apps Market is Booming & Expected to Grow at a CAGR of 19.2% to 2031

Dec 5 • 5 min read

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Mental Health Psychedelic Apps Market – (By Therapy Type (Music/ Creative/ Artistic, Visual/ Patterns/ Puzzle, Guidance/ Lifestyle), By O.S. Type (Android & iOS, iOS)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.” According to the latest research by InsightAce Analytic,…

Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial

Dec 1 • 4 min read

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced positive results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem, earlier this week. The treatment used in…

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Dec 1 • 2 min read

Cybin Inc. announced positive Phase 2 topline safety and efficacy data for CYB003, its proprietary deuterated psilocybin analog, being developed for the treatment of major depressive disorder (?MDD?). Summary of CYB003 Phase 2 topline efficacy data: Rapid and large improvements in symptoms of depression observed after single doses of CYB003?: An average of 13.75 points…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441